Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2 - Concepedia

Concepedia

Publication | Open Access

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

DOI Full Paper Access

272

Citations

21

References

2017

Year

Amit M. Oza, Anna V. Tinker, Ana Oaknin, Ronnie Shapira‐Frommer, Iain A. McNeish, Elizabeth M. Swisher, Isabelle Ray‐Coquard, Katherine M. Bell‐McGuinn, Robert L. Coleman, David M. O’Malley,

Gynecologic Oncology

Abstract

Rucaparib has antitumor activity in advanced BRCA1/2-mutated HGOC and a manageable safety profile.

References

	Year	Citations

Page 1